Dr. Frank V. Fossella

Get to Know Dr. Frank V. Fossella

Dr. Frank Fossella is a professor of medicine and internist within the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

He has served as the principal investigator for more than 50 clinical trials, most of which were aimed at finding a better, more effective treatment for patients with lung cancer, which is his specialty. He also treats patients with other thoracic cancers, including pleural mesothelioma.

Fossella graduated from the nearby Baylor College of Medicine after receiving his undergraduate degree from the Cornell University College of Arts and Sciences in New York. He also did his internal medicine residency and medical oncology fellowship at Baylor.

Close Button

Full Name

Diagnosis Please Select Mesothelioma Asbestosis Lung Cancer Other Unknown

Zip Code

Email

Phone Number

Preferred Method of Contact Please Select Call Text

Message

Full Name

By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

Get Connected Now

Find a Mesothelioma Specialist

Get specialized treatment from experienced mesothelioma doctors.

Find a Doctor Now

Specialties of Dr. Frank V. Fossella

• Pleural mesothelioma
• Lung cancer
• Clinical research

Dr. Frank V. Fossella’s Experience and Medical Education

• University of Texas MD Anderson Cancer Center
• Baylor College of Medicine (M.D.)
• Baylor College of Medicine Affiliated Hospitals (Residency and fellowship)

Awards and Certifications

• America’s Top Doctors for Cancer, Castle Connolly (2016-2020)
• America’s Top Doctors, Castle Connolly (2016-2020)
• Top Doctor, Houston Chronicle (2016-2017)
• America’s Top Doctors, Newsweek (2015)

Publications of Dr. Frank V. Fossella

• Gjyshi, O. et al. (2020, October). Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology.
• Hong, L. et al. (2020, September). Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology.
• Cascone, T. et al. (2020, July). A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research.